双等位基因抗原逃逸是多发性骨髓瘤对抗CD38抗体耐药的机制
研究分析701例新诊断、67例抗CD38抗体初治复发和50例抗CD38抗体治疗后复发多发性骨髓瘤患者的全基因组和全外显子测序数据,发现50例抗CD38治疗后复发患者中10例(20%)CD38缺失,其中3例双拷贝缺失;L153H和C275Y变异降低达雷妥尤单抗和伊沙妥昔单抗结合亲和力及抗体依赖细胞毒性,R140G变异仅对达雷妥尤单抗耐药而保留伊沙妥昔单抗敏感性。
要点
- 抗CD38治疗后复发患者中20%(10/50)出现CD38缺失,3例为双拷贝缺失。
- L153H和C275Y变异降低达雷妥尤单抗和伊沙妥昔单抗结合亲和力及抗体依赖细胞毒性。
- R140G变异仅对达雷妥尤单抗耐药,保留伊沙妥昔单抗敏感性。
核心结论
- 双等位CD38基因座破坏是抗CD38抗体耐药的肿瘤内在机制,部分患者可经二代测序指导后续治疗选择。
研究设计与样本
- 分析701例新诊断多发性骨髓瘤、67例抗CD38抗体初治复发和50例抗CD38抗体治疗后复发患者的全基因组和全外显子测序数据,并进行功能研究。
主要发现
- 50例抗CD38治疗后复发患者中10例(20%)CD38缺失,其中3例双拷贝缺失。
- 2例双等位CD38事件表现为不同亚克隆独立获得相似优势变异的趋同进化。
- L153H和C275Y变异降低达雷妥尤单抗和伊沙妥昔单抗的结合亲和力及抗体依赖细胞毒性。
- R140G变异对达雷妥尤单抗耐药,但保留对伊沙妥昔单抗的敏感性。
临床怎么用
- 作者认为二代测序可能对部分抗CD38抗体治疗后进展患者的后续治疗选择起作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). Although they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor-cell evasion in immunotherapy. Yet, it is unknown whether MM cells can develop permanent resistance to anti-CD38 antibodies by acquiring genomic events leading to biallelic disruption of the CD38 gene locus. Here, we analyzed whole-genome and whole-exome sequencing data from patients 701 newly diagnosed MM, 67 patients at relapse with naivety to anti-CD38 antibodies, and 50 patients collected at relapse after anti-CD38 antibodies. We report a loss of CD38 in 10 of 50 patients (20%) after CD38 therapy, 3 of whom exhibited a loss of both copies. Two of these cases showed convergent evolution in which distinct subclones independently acquired similar advantageous variants. Functional studies on missense mutations involved in biallelic CD38 events revealed that 2 variants, L153H and C275Y, decreased binding affinity and antibody-dependent cellular cytotoxicity of the commercial antibodies daratumumab and isatuximab. However, a third mutation, R140G, conferred selective resistance to daratumumab, while retaining sensitivity to isatuximab. Clinically, patients with MM are often rechallenged with CD38 antibodies after disease progression and these data suggest that next-generation sequencing may play a role in subsequent treatment selection for a subset of patients.
引用
- Diamond B, Baughn L, Poorebrahim M, et al. Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. Blood. 2025. PMID: 40493883. doi:10.1182/blood.2024028107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。